Actelion Buys Option To Acquire Trophos
Actelion Ltd. has paid €10 million for an option to acquire Trophos SA, a Marseille, France-based drug company focused on neurological disorders. The purchase price would be between €125 and €195 million. Trophos has raised VC funding from OTC Asset Management, CM-CIC Capital Prive, SGAM, Viveris Management, Turenne Capital Partners, Blue Medical and the Association Francaise contre les Myopathies.
21 July 2010•3 mins read
